MedTrace Logo

ARREST - A Phase I Study of SABR for Poly-metastatic Disease

NCT04530513 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2025-09-12

No results posted yet for this study

Summary

Stereotactic ablative radiotherapy (SABR) is a new radiation treatment that delivers high-dose, precise radiation to small areas in the body. This new technique can potentially allow radiation treatments to be focused more precisely, and be delivered more accurately than with older treatments. This improvement could help by reducing side effects overall (through radiation exposure to a smaller area of the body over a shorter time period), and by improving the chance of controlling the cancer by more precisely treating the cancer and by giving higher doses of radiation. SABR is considered a standard treatment for some lung cancers, and selected cancers that have spread to the brain. Ongoing studies are evaluating the use of SABR for treating people with up to 10 sites of cancer in the body, but its safety and value for treating patients with poly-metastatic cancer (more than 10 sites of cancer) is not yet known.

The purpose of this study is to determine the safety of using SABR to treat people with poly-metastatic disease. To our knowledge, this is the first time that SABR will be tested in people who have poly-metastatic disease.

Conditions

Interventions

RADIATION

Stereotactic ablative radiotherapy - Level 1

6Gy x 2 fractions to all sites in 2 weeks

RADIATION

Stereotactic ablative radiotherapy - Level 2

6Gy x 3 fractions to all sites in 3 weeks

RADIATION

Stereotactic ablative radiotherapy - Level 3

6Gy x 4 fractions to all sites in 4 weeks

RADIATION

Stereotactic ablative radiotherapy - Level 4

6Gy x 5 fractions to all sites in 5 weeks

RADIATION

Stereotactic ablative radiotherapy - De-escalation Level

6Gy x 1 fraction to all sites in 1 week

Sponsors & Collaborators

  • Ontario Institute for Cancer Research

    collaborator OTHER

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Glenn Bauman, MD · London Health Sciences Centre, Lawson Health Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-17
Primary Completion
2023-06-26
Completion
2025-06-15

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04530513 on ClinicalTrials.gov